
International Stem Cell Corporation – OTC:ISCO
International Stem Cell stock price today
International Stem Cell stock price monthly change
International Stem Cell stock price quarterly change
International Stem Cell stock price yearly change
International Stem Cell key metrics
Market Cap | 1.60M |
Enterprise value | 1.80M |
P/E | -5 |
EV/Sales | 0.14 |
EV/EBITDA | 9.31 |
Price/Sales | 0.13 |
Price/Book | -0.35 |
PEG ratio | -0.07 |
EPS | -0.06 |
Revenue | 7.83M |
EBITDA | -27K |
Income | -311K |
Revenue Q/Q | 2.06% |
Revenue Y/Y | -5.02% |
Profit margin | -2.8% |
Oper. margin | -1.04% |
Gross margin | 61.46% |
EBIT margin | -1.04% |
EBITDA margin | -0.34% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInternational Stem Cell stock price history
International Stem Cell stock forecast
International Stem Cell financial statements
Jun 2023 | 1.84M | 492K | 26.72% |
---|---|---|---|
Sep 2023 | 1.97M | -131K | -6.64% |
Dec 2023 | 1.88M | -458K | -24.25% |
Mar 2024 | 2.12M | -214K | -10.05% |
Jun 2023 | 5786000 | 9.63M | 166.47% |
---|---|---|---|
Sep 2023 | 5641000 | 9.5M | 168.41% |
Dec 2023 | 5390000 | 5.27M | 97.9% |
Mar 2024 | 5369000 | 5.33M | 99.33% |
Jun 2023 | 490K | -51K | 0 |
---|---|---|---|
Sep 2023 | 62K | -14K | 0 |
Dec 2023 | 161K | -3K | 0 |
Mar 2024 | -193K | -9K | 0 |
International Stem Cell alternative data
Aug 2023 | 29 |
---|---|
Sep 2023 | 29 |
Oct 2023 | 29 |
Nov 2023 | 29 |
Dec 2023 | 29 |
Jan 2024 | 29 |
Feb 2024 | 29 |
Mar 2024 | 29 |
Apr 2024 | 29 |
May 2024 | 29 |
Jun 2024 | 29 |
Jul 2024 | 29 |
International Stem Cell other data
Period | Buy | Sel |
---|---|---|
Jun 2018 | 0 | 1400 |
Jul 2018 | 0 | 3933 |
Aug 2018 | 0 | 14204 |
Oct 2018 | 0 | 1494 |
Dec 2018 | 0 | 12436 |
Jan 2019 | 599222 | 0 |
Apr 2019 | 0 | 1350 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | MAIER PAUL V director | Common Stock | 1,350 | N/A | N/A | ||
Purchase | SEMECHKIN ANDREY director, 10 perc.. | Common Stock | 599,222 | $1.75 | $1,048,639 | ||
Sale | GARNETTE SOPHIA officer: VP, Lega.. | Common Stock | 10,636 | $1.54 | $16,379 | ||
Option | GARNETTE SOPHIA officer: VP, Lega.. | Common Stock | 7,858 | $1.1 | $8,644 | ||
Option | GARNETTE SOPHIA officer: VP, Lega.. | Common Stock | 2,778 | $1.09 | $3,028 | ||
Option | GARNETTE SOPHIA officer: VP, Lega.. | Stock Option (Right to Buy) | 2,778 | $1.09 | $3,028 | ||
Option | GARNETTE SOPHIA officer: VP, Lega.. | Stock Option (Right to Buy) | 7,858 | $1.1 | $8,644 | ||
Option | KERN RUSSELL director, 10 perc.. | Common Stock | 1,800 | $1.09 | $1,962 | ||
Sale | KERN RUSSELL director, 10 perc.. | Common Stock | 1,800 | $1.09 | $1,962 | ||
Option | KERN RUSSELL director, 10 perc.. | Stock Option (Right to Buy) | 1,800 | $1.09 | $1,962 |
-
What's the price of International Stem Cell stock today?
One share of International Stem Cell stock can currently be purchased for approximately $0.18.
-
When is International Stem Cell's next earnings date?
Unfortunately, International Stem Cell's (ISCO) next earnings date is currently unknown.
-
Does International Stem Cell pay dividends?
No, International Stem Cell does not pay dividends.
-
How much money does International Stem Cell make?
International Stem Cell has a market capitalization of 1.60M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 4.78% to 7.79M US dollars.
-
What is International Stem Cell's stock symbol?
International Stem Cell Corporation is traded on the OTC under the ticker symbol "ISCO".
-
What is International Stem Cell's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of International Stem Cell?
Shares of International Stem Cell can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are International Stem Cell's key executives?
International Stem Cell's management team includes the following people:
- Ms. Sophia Garnette J.D. Vice President of Legal Affairs & Operations, Principal Financial Officer and Sec.(age: 41, pay: $169,960)
- Dr. Russell Kern Executive Vice President, Chief Scientific Officer & Director(age: 39, pay: $53,970)
- Dr. Andrey Semechkin Co-Chairman & Chief Executive Officer(age: 65, pay: $53,970)
-
How many employees does International Stem Cell have?
As Jul 2024, International Stem Cell employs 29 workers.
-
When International Stem Cell went public?
International Stem Cell Corporation is publicly traded company for more then 18 years since IPO on 8 Jan 2007.
-
What is International Stem Cell's official website?
The official website for International Stem Cell is internationalstemcell.com.
-
Where are International Stem Cell's headquarters?
International Stem Cell is headquartered at 5950 Priestly Drive, Carlsbad, CA.
-
How can i contact International Stem Cell?
International Stem Cell's mailing address is 5950 Priestly Drive, Carlsbad, CA and company can be reached via phone at +7 609406383.
International Stem Cell company profile:

International Stem Cell Corporation
internationalstemcell.comOTC
26
Biotechnology
Healthcare
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in North America, Asia, Europe, and internationally. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; and develops, manufactures, and markets anti-aging skincare and human cell culture products. The company's human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. The company sells skincare products through a website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.
Carlsbad, CA 92131
CIK: 0001355790
:
: